Anti-Polyoma virus, Medium T antigen antibody [PyMT] (ab15085)
Key features and details
- Rat monoclonal [PyMT] to Polyoma virus, Medium T antigen
- Suitable for: IP, ICC/IF, WB
- Isotype: IgG2b
Overview
-
Product name
Anti-Polyoma virus, Medium T antigen antibody [PyMT] -
Description
Rat monoclonal [PyMT] to Polyoma virus, Medium T antigen -
Host species
Rat -
Tested applications
Suitable for: IP, ICC/IF, WBmore details -
Species reactivity
Reacts with: Other species -
Immunogen
Synthetic peptide (N terminal).
-
General notes
Binds medium T antigen only, allows isolation of viral T antigens.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Constituent: PBS -
Concentration information loading...
-
Primary antibody notes
Binds medium T antigen only, allows isolation of viral T antigens. -
Clonality
Monoclonal -
Clone number
PyMT -
Myeloma
NS1 -
Isotype
IgG2b -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab15085 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IP |
Use at an assay dependent dilution.
|
|
ICC/IF |
Use at an assay dependent dilution.
|
|
WB | (1) |
Use at an assay dependent concentration.
|
Notes |
---|
IP
Use at an assay dependent dilution. |
ICC/IF
Use at an assay dependent dilution. |
WB
Use at an assay dependent concentration. |
Target
-
Relevance
Middle T antigen (MT) is a 421-amino-acid protein associated with membranes and underlying cytoskeletal elements, and is associated with a tyrosine-specific protein kinase activity. It is the principal oncoprotein of polyomavirus that is necessary and often sufficient for transformation in vitro. MT delivered as a transgene or a retrovirus can induce tumors in a wide variety of tissues. Polyomavirus (PyV) is a small, double-stranded, closed-circular-DNA virus with an approximately 5-kb genome divided into two roughly equal regions. The late transcripts produce the viral capsid proteins, whereas the early region encodes three so-called tumor (T) antigens that are important for both productive infection and transformation. -
Cellular localization
Cytoplasmic location in cells infected with virus. -
Database links
- Entrez Gene: 1489030 Other species
- Entrez Gene: 1489533 Other species
- SwissProt: P03077 Other species
- SwissProt: P03079 Other species
-
Alternative names
- Middle T antigen antibody
- MT AG antibody
- MT antibody
- Polyoma virus middle t antigen antibody
Protocols
Datasheets and documents
-
Datasheet download
References (17)
ab15085 has been referenced in 17 publications.
- DeVette CI et al. A pipeline for identification and validation of tumor-specific antigens in a mouse model of metastatic breast cancer. Oncoimmunology 9:1685300 (2020). PubMed: 32002300
- Fein MR et al. Cancer cell CCR2 orchestrates suppression of the adaptive immune response. J Exp Med 217:N/A (2020). PubMed: 32667673
- Li Y et al. Genetic Fate Mapping of Transient Cell Fate Reveals N-Cadherin Activity and Function in Tumor Metastasis. Dev Cell 54:593-607.e5 (2020). PubMed: 32668208
- Kim J et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705-1715 (2018). PubMed: 30349115
- Messenheimer DJ et al. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res 23:6165-6177 (2017). PubMed: 28855348